Error message
Notice: Undefined index: content in _drupal_default_html_head() (line 345 of /var/www/vhosts/rovi.es/httpdocs/includes/common.inc).
|
Date |
Title |
Description |
PDF |
|
22 Jun 2021 |
On significant placements in financial instruments |
Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share.
|
Download |
|
29 Apr 2021 |
On business and financial situation |
The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States.
|
Download |
|
12 Apr 2021 |
On business and financial situation |
The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine.
|
Download |
|
02 Mar 2021 |
On business and financial situation |
The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States
|
Download |
|
02 Mar 2021 |
On business and financial situation |
The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States
|
Download |
Pages
|
Date |
Title |
Description |
PDF |
|
10 May 2023 |
Announcement of General Shareholders’ Meeting |
ROVI releases the information related to its General Shareholders Meeting
|
Download |
|
10 Apr 2023 |
Liquidity and counterparty agreements |
Liquidity contract: transactions conducted in the first quarter of 2023
|
Download |
|
21 Feb 2023 |
Annual Corporate Governance Report |
ROVI releases the 2022 Annual Corporate Governance Report
|
Download |
|
21 Feb 2023 |
Annual Report regarding remuneration of the members of the Board of Directors |
ROVI releases the 2022 annual report regarding remuneration of the members of the Board of Directors
|
Download |
|
16 Feb 2023 |
On business and financial situation |
The Company informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone ISM®) in the United States.
|
Download |
Pages
|
Date |
Title |
Description |
PDF |
|
12 Jun 2013 |
Convocatorias y Acuerdos de Juntas y Asambleas Generales |
|
Download |
|
06 Jun 2013 |
Otros sobre negocio y situación financiera |
|
Download |
|
24 Apr 2013 |
Información sobre resultados (2) |
|
Download |
|
24 Apr 2013 |
Información sobre resultados |
|
Download |
|
24 Apr 2013 |
Convocatorias y Acuerdos de Juntas y Asambleas Generales |
|
Download |
Pages
